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BACKGROUND
Intermittent treatment with sulfadoxine–pyrimethamine is widely recommended for the 
prevention of malaria in pregnant women in Africa. However, with the spread of resistance 
to sulfadoxine–pyrimethamine, new interventions are needed.
METHODS
We conducted a double-blind, randomized, controlled trial involving 300 human immuno-
deficiency virus (HIV)–uninfected pregnant adolescents or women in Uganda, where sulfa-
doxine–pyrimethamine resistance is widespread. We randomly assigned participants to a 
sulfadoxine–pyrimethamine regimen (106 participants), a three-dose dihydroartemisinin–
piperaquine regimen (94 participants), or a monthly dihydroartemisinin–piperaquine regi-
men (100 participants). The primary outcome was the prevalence of histopathologically 
confirmed placental malaria.
RESULTS
The prevalence of histopathologically confirmed placental malaria was significantly higher in 
the sulfadoxine–pyrimethamine group (50.0%) than in the three-dose dihydroartemisinin–
piperaquine group (34.1%, P = 0.03) or the monthly dihydroartemisinin–piperaquine group 
(27.1%, P = 0.001). The prevalence of a composite adverse birth outcome was lower in the 
monthly dihydroartemisinin–piperaquine group (9.2%) than in the sulfadoxine–pyrimeth-
amine group (18.6%, P = 0.05) or the three-dose dihydroartemisinin–piperaquine group (21.3%, 
P = 0.02). During pregnancy, the incidence of symptomatic malaria was significantly higher in 
the sulfadoxine–pyrimethamine group (41 episodes over 43.0 person-years at risk) than in the 
three-dose dihydroartemisinin–piperaquine group (12 episodes over 38.2 person-years at risk, 
P = 0.001) or the monthly dihydroartemisinin–piperaquine group (0 episodes over 42.3 person-
years at risk, P<0.001), as was the prevalence of parasitemia (40.5% in the sulfadoxine–pyri-
methamine group vs. 16.6% in the three-dose dihydroartemisinin–piperaquine group [P<0.001] 
and 5.2% in the monthly dihydroartemisinin–piperaquine group [P<0.001]). In each treatment 
group, the risk of vomiting after administration of any dose of the study agents was less than 
0.4%, and there were no significant differences among the groups in the risk of adverse events.
CONCLUSIONS
The burden of malaria in pregnancy was significantly lower among adolescent girls or 
women who received intermittent preventive treatment with dihydroartemisinin–piperaquine 
than among those who received sulfadoxine–pyrimethamine, and monthly treatment with 
dihydroartemisinin–piperaquine was superior to three-dose dihydroartemisinin–piperaquine 
with regard to several outcomes. (Funded by the Eunice Kennedy Shriver National Institute 
of Child Health and Human Development; ClinicalTrials.gov number, NCT02163447.)
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In 2007, more than 30 million pregnan-cies were estimated to have occurred in areas of sub-Saharan Africa in which Plasmodium 
falciparum is endemic.1 Malaria during pregnancy 
is associated with placental malaria, adverse 
birth outcomes, and complications and death in 
both the mother and the infant.2,3 In sub-Saharan 
Africa, malaria during pregnancy is estimated to 
be the cause of low birth weight in up to 20% of 
deliveries, leading to more than 100,000 infant 
deaths annually.2,3 Given the high burden of 
malaria in this vulnerable population, the World 
Health Organization (WHO) recommends the 
routine implementation of malaria-preventive 
measures among pregnant women in all coun-
tries in Africa in which P. falciparum remains 
endemic. These measures include the use of 
long-lasting insecticide–treated bed nets and in-
termittent preventive treatment with sulfadoxine–
pyrimethamine during pregnancy.4
Earlier studies have shown that intermittent 
preventive treatment with sulfadoxine–pyrimeth-
amine during pregnancy is effective at reducing 
the risk of placental malaria, low birth weight, 
and maternal illness.5-8 However, resistance to 
sulfadoxine–pyrimethamine has become wide-
spread, especially in East Africa and southern 
Africa,9 and more recent studies have suggested 
that the effectiveness of this drug combination 
as intermittent preventive treatment during preg-
nancy may be compromised10-13; thus, there is a 
need for evaluation of alternatives to sulfadoxine–
pyrimethamine for such treatment during preg-
nancy. Studies of amodiaquine and mefloquine 
have not shown convincing evidence of superior 
benefit, and these drugs were found to have 
more adverse side effects than sulfadoxine–pyri-
methamine.14,15
Artemisinin-based combination therapies have 
been shown to be effective for the treatment of 
malaria during pregnancy16,17; however, there are 
limited data evaluating such regimens for use as 
intermittent preventive treatment during preg-
nancy. Dihydroartemisinin–piperaquine is an es-
pecially attractive combination therapy, given its 
prolonged post-treatment prophylactic effect.18 
Here, we compare the efficacy and safety of 
three different regimens as intermittent preven-
tive treatment during pregnancy — a regimen of 
sulfadoxine–pyrimethamine, a three-dose regi-
men of dihydroartemisinin–piperaquine, and a 
monthly regimen of dihydroartemisinin–pipera-
quine — among human immunodeficiency virus 
(HIV)–uninfected adolescent girls and women 
living in an area of Uganda in which the inten-
sity of malaria transmission and the prevalence of 
sulfadoxine–pyrimethamine resistance are high.
Me thods
Trial Setting, Participants, and Oversight
We conducted the trial in Tororo, Uganda, which 
is an area of high malaria-transmission intensity, 
with an estimated entomologic inoculation rate 
of 310 infectious bites per person-year.19 Eligible 
participants were HIV-uninfected pregnant ado-
lescents or women at least 16 years of age (pri-
migravid or multigravid), who were between 12 
and 20 weeks of gestation, as confirmed by ultra-
sonography. A complete list of the entry criteria 
is provided in the trial protocol, available with 
the full text of this article at NEJM.org. All trial 
participants provided written informed consent.
The trial was funded by the National Insti-
tutes of Health and approved by the ethics com-
mittees at Makerere University School of Bio-
medical Sciences, the Uganda National Council 
for Science and Technology, and the University 
of California, San Francisco. All the authors 
vouch for the completeness and accuracy of the 
data and analyses presented and for the fidelity 
of the trial to the protocol.
Trial Design and Randomization
This was a double-blind, randomized, three-group 
controlled trial comparing sulfadoxine–pyrimetha-
mine, three-dose dihydroartemisinin–piperaquine, 
and monthly dihydroartemisinin–piperaquine as 
intermittent preventive treatment for malaria in 
pregnancy. Randomization was performed in a 
1:1:1 ratio in permuted blocks of 6 or 12. Phar-
macists who were not otherwise involved in the 
trial were responsible for treatment assignment 
and the preparation of study agents. Six partici-
pants who were randomly assigned to receive 
three-dose dihydroartemisinin–piperaquine were 
treated with sulfadoxine–pyrimethamine because 
of a transcription error.
Each dose of sulfadoxine–pyrimethamine (tab-
lets of 500 mg of sulfadoxine and 25 mg of pyri-
methamine [Kamsidar, Kampala Pharmaceutical 
Industries]) consisted of three tablets taken to-
gether; doses were administered at three times 
during the pregnancy (the sulfadoxine–pyrimeth-
amine group). Each dose of dihydroartemisinin–
piperaquine (tablets of 40 mg of dihydroartemis-
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inin and 320 mg of piperaquine [Duo-Cotecxin, 
Holley-Cotec]) consisted of three tablets given 
once a day for 3 consecutive days; doses were 
administered either three times during the preg-
nancy (the three-dose dihydroartemisinin–piper-
aquine group) or once per month (the monthly 
dihydroartemisinin–piperaquine group). Partici-
pants who were assigned to the sulfadoxine–
pyrimethamine group or the three-dose dihydro-
artemisinin–piperaquine group received active 
study agents at 20, 28, and 36 weeks of gesta-
tion. Participants who were assigned to the 
monthly dihydroartemisinin–piperaquine group 
received active study agents every 4 weeks start-
ing at 16 or 20 weeks of gestation. Placebos of 
sulfadoxine–pyrimethamine and dihydroartemis-
inin–piperaquine were used such that every 
4 weeks, participants received the same number 
of pills with the same appearance. Administra-
tion of the first daily doses of active agents or 
placebo were directly observed in the clinic, and 
the second and third daily doses were adminis-
tered at home. Additional details regarding the 
administration of the study agents are provided 
in the trial protocol.
Trial Procedures
At enrollment, participants received a net treated 
with long-lasting insecticide, underwent a stan-
dardized examination, and had blood samples 
collected. Participants received all their medical 
care at a study clinic that was open every day. 
Routine visits were scheduled every 4 weeks and 
included collection of blood for dried blood 
spots to be used for future molecular testing; 
routine laboratory testing (complete blood count 
and measurement of alanine aminotransferase 
levels) was performed every 8 weeks. Partici-
pants were encouraged to come to the clinic any 
time they were ill. Those who presented with a 
documented fever (tympanic temperature, ≥38.0°C) 
or history of fever in the previous 24 hours had 
blood collected for a thick blood smear. If the 
smear was positive for parasites, malaria was 
diagnosed and treated with artemether–lume-
fantrine.
Participants were encouraged to deliver at the 
hospital adjacent to the study clinic. Participants 
who delivered at home were visited by trial staff 
at the time of delivery or as soon as possible 
afterward. At delivery, a standardized assess-
ment was completed, including evaluation of the 
neonate for congenital anomalies, measurement 
of birth weight, and collection of biologic speci-
mens, including placental tissue, placental blood, 
cord blood, and maternal blood. After delivery, 
participants were followed for 6 weeks. Adverse 
events were assessed and graded according to 
standardized criteria at every visit to the study 
clinic.20 Electrocardiography was performed to 
assess corrected QT (QTc) intervals with the use 
of the Fridericia’s formula in 42 participants just 
before their first daily dose of study agents and 
3 to 4 hours after their third daily dose of study 
agents when they reached 28 weeks of gestation.
Laboratory Procedures
Blood smears were collected from febrile partici-
pants during pregnancy and from placental, cord, 
and maternal blood at delivery. Blood smears 
were stained with 2% Giemsa and read by expe-
rienced laboratory technologists. A blood smear 
was considered to be negative when the exami-
nation of 100 high-power fields did not reveal 
asexual parasites. For quality control, all slides 
were read by a second microscopist, and a third 
reviewer was designated to settle any discrep-
ancy between readings. The rate of agreement 
between the readers was 98.6% (kappa, 0.96; 
P<0.001). Blood samples for dried blood spots 
were obtained from participants at enrollment 
and every 4 weeks during pregnancy, as well as 
from placental blood, cord blood, and maternal 
blood at delivery. Dried blood spots were tested 
for the presence of malaria parasites with the 
use of a loop-mediated isothermal amplification 
(LAMP) kit (Eiken Chemical), as described previ-
ously.21 Placental tissues were processed for his-
tologic evidence of placental malaria as described 
previously.22 Histopathological slides were read 
in duplicate by two independent readers, and the 
results were recorded on a standardized case-
record form; any discrepant results were resolved 
by a third reader. The rate of inter-reader agree-
ment was 71.3% (kappa, 0.48; P<0.001). The 
readers were unaware of both the treatment as-
signment and the results of previous reads.
Trial Outcomes
The primary outcome was the prevalence of 
placental malaria, as assessed by the presence 
of any parasites or malaria pigment detected his-
topathologically. The histopathological assess-
ment of placenta was also classified according to 
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the standardized system developed by Rogerson 
et al.23 and according to whether moderate-to-
high-grade pigment deposition was present (de-
fined as pigment detected in ≥5% of high-power 
fields).24 Secondary outcomes included the inci-
dence of symptomatic malaria; the prevalence of 
parasitemia assessed by means of LAMP; the 
prevalence of anemia (hemoglobin level, <11 g per 
deciliter) during pregnancy after the administra-
tion of the first dose of study agent; the preva-
lence of parasitemia at delivery assessed by 
means of microscopy and LAMP in samples of 
placental, cord, and maternal blood; and adverse 
birth outcomes, including spontaneous abortion, 
stillbirth, low birth weight (<2500 g), preterm 
delivery (<37 weeks), congenital anomaly, and a 
composite of any of these birth outcomes. For 
participants who gave birth to twins, the deliv-
ery outcomes were based on whether the outcome 
was present in either child or in the placenta. 
Measures of safety and side-effect profiles in-
cluded the prevalence of vomiting after adminis-
tration of study agents and the incidence of ad-
verse events after the initiation of study agents 
through 6 weeks post partum.
Statistical Analysis
To test the hypothesis that the use of intermit-
tent preventive treatment during pregnancy with 
either three-dose dihydroartemisinin–piperaquine 
or monthly dihydroartemisinin–piperaquine would 
be associated with a lower risk of histopatho-
logically confirmed placental malaria than that 
associated with sulfadoxine–pyrimethamine, we 
assumed a prevalence of placental malaria of 
62% in the sulfadoxine–pyrimethamine group 
on the basis of previous data and calculated that 
a sample size of 300 would be required for the 
study to have 80% power to show a 33% lower 
prevalence with dihydroartemisinin–piperaquine, 
at a two-sided significance level of 0.05. Statisti-
cal analyses were performed with Stata software, 
version 12 (StataCorp). All analyses were per-
formed in the modified intention-to-treat popu-
lation, which included all participants who were 
randomly assigned to a treatment group and 
who had outcomes of interest that could be 
evaluated. Comparisons of simple proportions 
were made with the chi-square test or Fisher’s 
exact test. Comparisons of proportions with re-
peated measures were made with generalized 
estimating equations, with the use of log-bino-
mial regression and robust standard errors. 
Comparisons of incidence measures were made 
with a negative binomial regression model. All 
P values were two-sided, and a P value of less 
than 0.05 was considered to indicate statistical 
significance.
R esult s
Trial Participants and Follow-up
From June through October 2014, a total of 386 
adolescent girls and women were screened, and 
300 were enrolled and underwent randomiza-
tion; 106 enrollees were assigned to the sulfa-
doxine–pyrimethamine group, 94 to the three-
dose dihydroartemisinin–piperaquine group, and 
100 to the monthly dihydroartemisinin–pipera-
quine group (Fig. 1). The baseline characteristics 
were similar among the three treatment groups 
(Table 1). The mean age at enrollment was 22 
years, 69% of the participants were enrolled at 
16 weeks of gestation or earlier, 37% were pri-
migravid, 87% reported owning a long-lasting 
insecticide–treated net, and 57% had malaria 
parasites detected by LAMP. A total of 289 par-
ticipants (96.3%) were followed through deliv-
ery, and 282 (94.0%) had placental tissue col-
lected for histopathological assessment (Fig. 1). 
Eight participants gave birth to twins; four of 
these twin births had dichorionic placentas.
Efficacy Outcomes
At delivery, the prevalence of any histopathologi-
cally confirmed placental malaria was signifi-
cantly higher in the sulfadoxine–pyrimethamine 
group (50.0%) than in the three-dose dihydro-
artemisinin–piperaquine group (34.1%, P = 0.03) 
or the monthly dihydroartemisinin–piperaquine 
group (27.1%, P = 0.001) (Table 2). All 105 pla-
centas that were positive for placental malaria 
had pigment in fibrin that was indicative of past 
infection, but only 7 had parasites indicative of 
concomitant active infection. The prevalence of 
moderate-to-high-grade pigment deposition was 
significantly higher in the sulfadoxine–pyrimeth-
amine group (33.7%) than in the three-dose 
dihydroartemisinin–piperaquine group (18.2%, 
P = 0.02) or the monthly dihydroartemisinin–
piperaquine group (8.3%, P<0.001) (Table S1 in 
the Supplementary Appendix, available at NEJM 
.org). When only primigravid participants were 
considered, the prevalence of any histologically 
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confirmed placental malaria was similar among 
the three treatment groups, but the prevalence of 
moderate-to-high-grade pigment deposition was 
significantly higher in the sulfadoxine–pyrimeth-
amine group than in the monthly dihydroarte-
misinin–piperaquine group (55.6% vs. 20.6%, 
P = 0.003). The prevalence of histopathologically 
confirmed placental malaria was much lower 
among multigravid participants than among 
primigravid participants, and among multigravid 
participants, the prevalence of any histopatho-
logically confirmed placental malaria and 
moderate-to-high-grade pigment deposition was 
significantly higher in the sulfadoxine–pyrimeth-
amine group than in the three-dose dihydro-
artemisinin–piperaquine group or the monthly 
dihydroartemisinin–piperaquine group (Fig. S1 
in the Supplementary Appendix). Detection of 
malaria parasites by means of microscopy in 
placental and maternal blood was uncommon, 
Figure 1. Enrollment, Randomization, and Follow-up.
DP denotes dihydroartemisinin–piperaquine, and SP sulfadoxine–pyrimethamine.
300 Underwent randomization
386 Pregnant adolescents or women
were assessed for eligibility
86 Were excluded
36 Received SP before or antimalarial therapy
during pregnancy
25 Were at >20 wk of gestation
11 Were HIV-positive
3 Intended to move outside the study area
2 Were at <12 wk of gestation
2 Had chronic medical condition
2 Were <16 yr of age
1 Had nonviable pregnancy
1 Had early or active labor
1 Had residence >30 km from clinic
1 Did not plan to deliver in the hospital
1 Was unwilling to avoid medications outside
protocol
106 Were assigned to receive SP 100 Were assigned to receive monthly DP
102 Were followed through delivery 98 Were followed through delivery
94 Were assigned to receive three-dose DP
4 Were withdrawn before 
delivery
1 Could not be located for
>60 days
2 Moved out of study area
1 Became infected with HIV
5 Were withdrawn before
delivery
3 Could not be located for
>60 days
2 Moved out of study area
2 Were withdrawn before
delivery
1 Could not be located for
>60 days
1 Moved out of study area
89 Were followed through delivery
98 Were included in primary analysis 96 Were included in primary analysis
4 Did not have samples
collected for placental
histopathological
assessment
1 Did not have samples
collected for placental
histopathological
assessment
2 Did not have samples
collected for placental
histopathological
assessment
88 Were included in primary analysis
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with no significant differences among the treat-
ment groups. However, detection of malaria 
parasites by LAMP in placental and maternal 
blood was significantly more common in the 
sulfadoxine–pyrimethamine group than in the 
three-dose dihydroartemisinin–piperaquine group 
or the monthly dihydroartemisinin–piperaquine 
group (Table 2).
A total of 72 adverse birth outcomes occurred 
in 47 participants (Table S2 in the Supplemen-
tary Appendix). Low birth weight was the most 
common adverse birth outcome (36 instances), 
followed by preterm delivery (24), congenital 
anomaly (6), stillbirth (3), and spontaneous 
abortion (3). There were no significant differ-
ences in individual birth outcomes among the 
treatment groups, but the risk of any adverse 
birth outcome was significantly lower in the 
monthly dihydroartemisinin–piperaquine group 
(9.2%) than in the three-dose dihydroartemis-
inin–piperaquine group (21.3%, P = 0.02); the risk 
was also lower in the monthly dihydroartemis-
inin–piperaquine group than that in the sulfa-
doxine–pyrimethamine group (18.6%), but the 
Characteristic
Sulfadoxine–
Pyrimethamine 
(N = 106)
Three-Dose 
Dihydroartemisinin–
Piperaquine 
(N = 94)
Monthly 
Dihydroartemisinin–
Piperaquine 
(N = 100)
Age — yr 21.3±3.6 22.2±4.3 22.6±4.0†
Gestation — wk 15.2±2.0 15.4±2.0 15.5±2.1
12 to 16 wk — no. (%) 75 (70.8) 65 (69.2) 67 (67.0)
>16 to 20 wk — no. (%) 31 (29.3) 29 (30.9) 33 (33.0)
Gravidity — no. (%)‡
1 42 (39.6) 33 (35.1) 36 (36.0)
2 32 (30.2) 28 (29.8) 28 (28.0)
≥3 32 (30.2) 33 (35.1) 36 (36.0)
Bed-net ownership — no. (%)
None 13 (12.3) 8 (8.5) 9 (9.0)
Untreated net 1 (0.9) 6 (6.4) 2 (2.0)
Long-lasting insecticide–treated net 92 (86.8) 80 (85.1) 89 (89.0)
Household wealth index — no. (%)
Lowest third 38 (35.9) 29 (30.9) 33 (33.0)
Middle third 32 (30.2) 37 (39.4) 31 (31.0)
Highest third 36 (34.0) 28 (29.8) 36 (36.0)
Weight — kg 55.4±6.8 55.6±7.0 55.5±7.5
Height — cm 162.8±6.8 162.5±6.7 162.3±7.7
Laboratory values
White-cell count per mm3 6036±2070 6279±1713 6040±1572
Neutrophil count per mm3 3330±1477 3558±1304 3351±1175
Platelet count per mm3 198,906±60,665 201,809±67,358 195,840±59,593
Hemoglobin level — g/dl 11.8±1.5 11.9±1.1 12.0±1.4
Alanine aminotransferase level — IU/liter 15.4±7.5 14.9±5.8 14.7±5.6
Detection of malaria parasites by LAMP — no. (%) 59 (55.7) 55 (59.1)§ 57 (57.0)
*  There were no significant differences among the groups at baseline, except as noted. LAMP denotes loop-mediated isothermal amplification.
†  The difference between the sulfadoxine–pyrimethamine group and the monthly dihydroartemisinin–piperaquine group was significant (P = 0.02).
‡  Gravidity is the number of times a woman has been pregnant (including the pregnancy in this trial).
§  Data are missing for 1 woman.
Table 1. Baseline Characteristics of the Study Participants at Enrollment.*
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difference was of borderline significance (P = 0.05) 
(Table 2). A full comparison of efficacy out-
comes between the three-dose dihydroartemis-
inin–piperaquine group and the monthly dihydro-
artemisinin–piperaquine group is provided in 
Table S3 in the Supplementary Appendix.
After the initiation of treatment, the incidence 
of symptomatic malaria during pregnancy was 
significantly higher in the sulfadoxine–pyrimeth-
amine group (41 episodes in 32 participants) 
than in the three-dose dihydroartemisinin–
piperaquine group (12 episodes in 11 partici-
pants, P = 0.001) or the monthly dihydroartemis-
inin–piperaquine group (0 episodes, P<0.001) 
(Table 2). The prevalence of parasitemia was also 
significantly higher in the sulfadoxine–pyrimeth-
amine group (40.5%) than in the three-dose 
dihydroartemisinin–piperaquine group (16.6%, 
P<0.001) or the monthly dihydroartemisinin–
piperaquine group (5.2%, P<0.001) (Table 2 and 
Fig. 2). The risk of maternal anemia was signifi-
cantly higher in the sulfadoxine–pyrimethamine 
group (34.9%) than in the monthly dihydroarte-
misinin–piperaquine group (23.6%, P = 0.04), 
but it was not significantly higher than in the 
three-dose dihydroartemisinin–piperaquine group 
(30.4%, P = 0.43) (Table 2).
Side Effects and Safety Outcomes
Overall, among all the treatment groups, vomit-
ing occurred less than 0.2% of the time after 
administration of any dose of the study agents, 
with no significant differences among the treat-
ment groups (Table 3). There were no significant 
differences in the incidence of any adverse 
events apart from dysphagia, which was more 
common in the monthly dihydroartemisinin–
piperaquine group than in the three-dose dihy-
droartemisinin–piperaquine group. All episodes 
of dysphagia were mild in severity, and we are 
not aware of any previous reports of dihydro-
artemisinin–piperaquine being associated with 
dysphagia. One grade 3 or 4 adverse event was 
thought by the investigators to be possibly re-
lated to the study agents: an episode of anemia 
that occurred after both the first and second 
doses of monthly dihydroartemisinin–piperaquine 
(study agents were subsequently withheld after 
the second dose) (Table 3). Among 42 partici-
pants who underwent electrocardiographic eval-
uation at 28 weeks of gestation, all pretreatment 
and post-treatment QTc intervals were within 
normal limits (≤450 msec), and no clinical ad-
verse events consistent with cardiotoxicity oc-
curred during the course of the study. The me-
dian change in QTc interval was greater in the 
three-dose dihydroartemisinin–piperaquine group 
(20 msec) and monthly dihydroartemisinin–
piperaquine group (30 msec) than in the sulfa-
doxine–pyrimethamine group (5 msec), but 
these differences were not significant (Table S4 
in the Supplementary Appendix).
Discussion
In this double-blind, randomized, controlled 
trial of intermittent preventive treatment of ma-
laria during pregnancy, the burden of malaria 
during pregnancy in the sulfadoxine–pyrimeth-
amine group (the current standard of care) was 
almost 1 episode of symptomatic malaria per 
person-year, with a prevalence of parasitemia 
higher than 40% during pregnancy, a prevalence 
of histopathologically confirmed placental ma-
laria of 50%, and a prevalence of any adverse 
birth outcome of almost 20%. The incidence of 
symptomatic malaria, the prevalence of parasit-
emia during pregnancy, and the prevalence of 
histopathologically confirmed placental malaria 
were lower in the group that received the three-
dose dihydroartemisinin–piperaquine regimen 
and in the group that received the monthly dihy-
Figure 2. Prevalence of Parasitemia during Pregnancy, According to Week  
of Gestation.
The data at 16 weeks include only participants who were enrolled on or be-
fore this time point (207 adolescent girls or women). For the SP and three-
dose DP groups, active drug was given at weeks 20, 28, and 36, and place-
bo was given at weeks 16, 24, 32, and 40. The prevalence of parasitemia 
was assessed by means of loop-mediated isothermal amplification (LAMP).
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droartemisinin–piperaquine regimen than in the 
group that received the sulfadoxine–pyrimeth-
amine regimen. In addition, the risk of maternal 
anemia was lower — and the risk of any adverse 
birth outcome was marginally lower — in the 
monthly dihydroartemisinin–piperaquine group 
than in the sulfadoxine–pyrimethamine group. 
Monthly dihydroartemisinin–piperaquine was 
associated with a lower incidence of symptom-
atic malaria, a lower prevalence of parasitemia 
during pregnancy, less moderate-to-high-grade 
placental pigment deposition, and a lower risk of 
any adverse birth outcome than was three-dose 
dihydroartemisinin–piperaquine, which suggests 
Outcome
Sulfadoxine–
Pyrimethamine
Three-Dose 
Dihydroartemisinin–
Piperaquine
Monthly 
Dihydroartemisinin–
Piperaquine
no. of events/total no. of doses (%)
Vomiting after administration of study agent
Observed after administration of first dose in clinic 2/617 (0.3) 0/542 1/594 (0.2)
Reported after administration of second or third dose at home 2/1222 (0.2) 0/1067 5/1180 (0.4)
no. of events (incidence per person-year at risk)
Adverse event of any severity*
Abdominal pain 172 (3.14) 122 (2.52) 132 (2.47)
Cough 94 (1.72) 71 (1.47) 77 (1.44)
Headache 90 (1.64) 70 (1.45) 78 (1.46)
Chills 21 (0.38) 14 (0.29) 12 (0.22)
Diarrhea 12 (0.22) 10 (0.21) 13 (0.24)
Malaise 16 (0.29) 9 (0.19) 8 (0.15)
Dysphagia 9 (0.16) 2 (0.04) 14 (0.26)†
Vomiting 8 (0.15) 8 (0.17) 8 (0.15)
Nausea 2 (0.04) 4 (0.08) 2 (0.04)
Urinary tract infection 3 (0.05) 2 (0.04) 2 (0.04)
Anorexia 2 (0.04) 0 4 (0.07)
Grade 3 or 4 adverse event
Anemia 12 (0.22) 4 (0.08) 6 (0.11)
Congenital anomaly 2 (0.04) 4 (0.08) 0
Stillbirth 1 (0.02) 1 (0.02) 1 (0.02)
Thrombocytopenia 2 (0.04) 0 0
Vaginal bleeding during second trimester 1 (0.02) 0 0
Retained products of conception 0 1 (0.02) 0
Preeclampsia 0 0 1 (0.02)
Hypotension 0 0 1 (0.02)
Pyelonephritis 0 1 (0.02) 0
Respiratory distress 0 1 (0.02) 0
All grade 3 or 4 adverse events 18 (0.33) 12 (0.25) 9 (0.17)
Grade 3 or 4 adverse events possibly related to study agents 0 0 1 (0.02)
All serious adverse events 6 (0.11) 9 (0.19) 4 (0.07)
*  Only categories with at least 5 total events are included.
†  P = 0.02 for the comparison of monthly dihydroartemisinin–piperaquine versus three-dose dihydroartemisinin–piperaquine.
Table 3. Safety and Adverse Effects.
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that the efficacy of this drug combination is 
higher with more frequent dosing. All three 
treatment regimens were associated with a low 
risk of vomiting, and there were no clinically 
significant differences in the rates of adverse 
events.
The burden of malaria in the sulfadoxine–
pyrimethamine group was not surprising, given 
the prevalence of molecular markers of sulfadox-
ine–pyrimethamine resistance in East Africa.9,25-27 
Observational studies from East Africa suggest-
ed that the use of sulfadoxine–pyrimethamine as 
intermittent preventive treatment during preg-
nancy provided minimal or no benefit,10,12,13 and 
in a randomized trial involving young Ugandan 
children, intermittent preventive treatment with 
monthly sulfadoxine–pyrimethamine provided 
no protection against malaria.28 A few controlled 
trials have evaluated alternatives to sulfadoxine–
pyrimethamine, including amodiaquine and me-
floquine, for intermittent preventive treatment 
during pregnancy; however, they have not shown 
convincing evidence of higher efficacy, and the 
drugs had a poor side-effect profile.14,15
Dihydroartemisinin–piperaquine has been 
shown to be effective for the treatment of ma-
laria in pregnant and nonpregnant populations29,30 
and for the prevention of malaria in children 
and nonpregnant adults.28,31 In addition to our 
trial, one other trial has evaluated the use of di-
hydroartemisinin–piperaquine for the prevention 
of malaria in pregnancy in an area of western 
Kenya with high levels of resistance to sulfa-
doxine–pyrimethamine.32 In that trial, HIV-unin-
fected pregnant women were randomly assigned 
to receive intermittent screening and treatment 
with dihydroartemisinin–piperaquine or inter-
mittent preventive treatment with a median of 
three doses of either dihydroartemisinin–pipera-
quine or sulfadoxine–pyrimethamine. Intermit-
tent screening and treatment with dihydroarte-
misinin–piperaquine was not found to be a 
suitable alternative to intermittent treatment 
with sulfadoxine–pyrimethamine; however, inter-
mittent treatment with dihydroartemisinin–
piperaquine was associated with a lower preva-
lence of malaria infection at delivery and a lower 
incidence of malaria infection and clinical ma-
laria during pregnancy than was sulfadoxine–
pyrimethamine. One of the strengths of our 
trial was the detailed longitudinal assessment of 
the risk of malaria during pregnancy and of the 
way in which effective intermittent preventive 
treatment during pregnancy affects outcomes 
assessed at delivery. At enrollment, almost 60% 
of the participants had evidence of asymptom-
atic parasitemia, which has been associated with 
an increased risk of placental malaria and ad-
verse birth outcomes.33,34 Dihydroartemisinin–
piperaquine was associated with a lower risk of 
symptomatic malaria and parasitemia than was 
sulfadoxine–pyrimethamine, and treatment with 
dihydroartemisinin–piperaquine was therefore 
associated with a lower risk of placental malaria. 
Furthermore, the use of a higher frequency of 
dosing — every 4 weeks starting as early as 16 
weeks of gestation (monthly dihydroartemisinin–
piperaquine) rather than every 8 weeks (three-
dose dihydroartemisinin–piperaquine) — was 
associated with an even lower risk of malaria 
during pregnancy and therefore with a lower 
risk of moderate-to-high-grade pigment deposi-
tion and improvements in birth outcomes. How-
ever, among primigravid participants, who are at 
the highest risk for placental malaria, the risk of 
low-grade pigment deposition associated with 
monthly dihydroartemisinin–piperaquine was not 
lower than that associated with the other two 
regimens; this suggests the need for effective 
preventive measures as early in pregnancy as 
possible.
Safety and side effects are important consid-
erations when preventive drugs are being evalu-
ated for routine use during pregnancy. In this 
trial, no clinically important differences in the 
risk of adverse events were observed among the 
treatment groups. Indeed, in a large systematic 
review, no safety concerns were identified in as-
sociation with dihydroartemisinin–piperaquine 
when it is administered for the treatment of 
malaria and when it is given monthly for the 
prevention of malaria in young children and 
adults.28,29,31,35 Dihydroartemisinin–piperaquine has 
been shown to cause prolongation of the QTc 
interval,36; however, in the limited number of 
participants in whom the QTc interval was 
evaluated in this trial, dihydroartemisinin–
piperaquine was not associated with any clini-
cally significant prolongation of the QTc interval.
In summary, in a high-transmission setting 
with widespread resistance to sulfadoxine–pyri-
methamine, intermittent preventive treatment 
with dihydroartemisinin–piperaquine during preg-
nancy resulted in a lower burden of malaria than 
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did treatment with sulfadoxine–pyrimethamine. 
The use of a higher dosing frequency of dihydro-
artemisinin–piperaquine (every 4 weeks starting 
as early as 16 weeks of gestation) provided more 
protection, which is in line with updated WHO 
policy recommendations that intermittent pre-
ventive treatment in pregnancy should be given 
at every antenatal clinic visit if visits are at least 
1 month apart.4 Additional and larger evaluations 
in different settings are needed to inform im-
portant questions regarding safety and the po-
tential risks for selection of drug-resistant 
parasites as a result of an increase in drug 
pressure.
The findings and conclusions in this report are those of the 
authors and do not necessarily represent the official position of 
Centers for Disease Control and Prevention.
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